Health / Investing

Acumen Stock Drops Sharply After Alzheimer’s Study Setback

The company put its Sept. 30 total at $78.6 million, counting cash, cash equivalents and marketable securities, and expected the funds to cover clinical and operating work into early 2027.

By Naomi CalderOct 30, 2026, 2:42 PM UTC

Updated Oct 30, 2026, 2:42 PM UTC1 min read

An office building housing Acumen Pharmaceuticals’ headquarters stands on Washington Street in Newton, Massachusetts. (AI-generated image / EconoTimes)

Acumen said sabirnetug missed the primary and key secondary endpoints in its ALTITUDE-AD study. ABOS fell more than 80% in premarket trading Friday.

ABOS was $0.2850 as of 14:35 UTC. The midstage study tested sabirnetug, Acumen’s lead candidate, in patients with Alzheimer’s disease.

Acumen’s third-quarter results listed $78.6 million in marketable securities, cash equivalents and cash as of Sept. 30. The company said that balance was expected to support clinical and operating work into early 2027.

Alzheimer’s disease Acumen Pharmaceuticals sabirnetug ALTITUDE-AD ABOS

View all

Health

Eisai Plans Five-Year Lecanemab Findings and Clinic Studies at CTAD

The program includes long-term trial follow-up, analyses of use at U.S. treatment centers and safety research across countries.

By Naomi CalderOct 30, 2026, 7:31 AM UTC

Health

Eli Lilly Licenses ADDF Speech Dataset for Alzheimer’s Research

SpeechDx links quarterly voice recordings with clinical and biomarker records from more than 2,000 participants in a three-year program.

By Naomi CalderOct 28, 2026, 8:35 PM UTC

Health

FDA Starts Neuroscience Program With Alzheimer’s Prevention as First Focus

The Alzheimer’s Prevention Accelerator will explore trial populations, disease-stage measures and evidence needed to show whether a product prevents or delays cognitive decline.

By Naomi CalderOct 23, 2026, 5:00 AM UTC